Link-Asia International Medtech Group Ltd. (1143) AI Stock Analysis

• Market Cap: HK$96.44M
• Dividend Yield: N/A
• Average Volume (3M): 785.58K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.64
• Revenue Growth: -25.16%
• EPS Growth: -160.31%
• Country: HK
• Employees: 835
• Sector: Technology
• Sector Strength: 88
• Industry: Consumer Electronics
• EPS (TTM): -0.07
• Shares Outstanding: 224,289,180
• 10 Day Avg. Volume: 1,134,204
• 30 Day Avg. Volume: 785,581
• PEG Ratio: 0.29
• Price to Book (P/B): 0.13
• Price to Sales (P/S): 0.14
• P/FCF Ratio: -0.89
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 51 Neutral
• Price Target: HK$0.50 ▲(25.00% Upside)

Link-Asia International Medtech Group Ltd. has a mixed outlook. The most significant factor is its financial performance, which shows stability in equity but challenges in revenue and cash flow. Technical analysis suggests a positive short-term trend, but valuation concerns due to negative profitability weigh heavily on the overall score.

Link-Asia International Medtech Group Ltd. Business Overview & Revenue Model

Company Description

Link-Asia International Medtech Group Ltd. (1143) is a Hong Kong-based company focused on the medical technology sector, primarily specializing in the development, manufacturing, and distribution of innovative medical devices and solutions. The company engages in various sectors, including surgical instruments, diagnostic equipment, and healthcare technologies, aiming to improve patient outcomes and streamline healthcare processes. Link-Asia is committed to leveraging advanced technologies and partnerships to enhance its product offerings and expand its market presence.

How the Company Makes Money

Link-Asia International Medtech Group Ltd. generates revenue through multiple streams, primarily by selling its medical devices and technologies to healthcare providers, hospitals, and clinics. The company's revenue model is centered around direct sales, distribution agreements, and partnerships with healthcare institutions. Additionally, Link-Asia may engage in research and development collaborations, potentially leading to licensing agreements for new technologies. The company's financial performance can also be influenced by government contracts or grants, industry partnerships, and the overall demand for medical technology solutions in the markets it serves.

Link-Asia International Medtech Group Ltd. Financial Statement Overview

Summary

Link-Asia International Medtech Group Ltd. shows a mixed financial profile with stable equity but challenges in revenue and cash flow consistency. The positive EBIT margin in 2024 is a positive sign, but overall profitability and cash flow management need improvement.

Income Statement

Link-Asia International Medtech Group Ltd. has shown mixed results over recent years. The company experienced declining revenues with a negative growth trend from 2019 to 2024, particularly from 2021 to 2024. While gross profit margins remained relatively stable, net profit margins were volatile, indicating potential profitability issues. The positive EBIT margin in 2024 is a welcome improvement, although historical EBIT margins were negative.

Balance Sheet

The company's balance sheet reveals a stable equity position with a moderate debt-to-equity ratio, indicating a balanced capital structure. The equity ratio has improved over time, suggesting a strengthening financial foundation. However, the fluctuating total debt and liabilities pose potential risks to financial stability.

Cash Flow

Cash flow analysis indicates inconsistent cash flow management. Operating cash flow was negative in several years, impacting free cash flow generation. Though there was a significant improvement in free cash flow in 2022, the lack of consistent positive cash flow raises concerns about long-term liquidity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	402.85M	479.32M	502.00M	529.25M	675.52M	595.02M
Gross Profit	90.89M	123.60M	136.87M	101.40M	144.89M	154.71M
EBITDA	14.14M	4.78M	40.49M	-14.06M	-4.54M	-116.52M
Net Income	-4.33M	8.04M	5.26M	-54.04M	-46.40M	-173.05M
Balance Sheet
Total Assets	875.18M	880.14M	776.42M	659.23M	677.98M	657.40M
Cash, Cash Equivalents and Short-Term Investments	331.35M	312.05M	271.57M	252.21M	146.80M	167.66M
Total Debt	94.77M	86.60M	26.75M	51.08M	61.20M	70.19M
Total Liabilities	343.00M	343.25M	287.69M	297.22M	311.98M	361.47M
Stockholders Equity	532.05M	536.53M	486.66M	359.86M	365.88M	295.46M
Cash Flow
Free Cash Flow	-47.91M	-75.67M	-132.09M	99.60M	-122.55M	-45.85M
Operating Cash Flow	-43.60M	-73.19M	-129.29M	107.55M	-100.45M	-15.04M
Investing Cash Flow	15.74M	49.83M	48.86M	2.13M	3.31M	-96.19M
Financing Cash Flow	55.49M	66.31M	101.84M	4.68M	74.19M	35.17M

Link-Asia International Medtech Group Ltd. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.40
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1143, the sentiment is Positive. The current price of 0.4 is below the 20-day moving average (MA) of 0.41, below the 50-day MA of 0.41, and above the 200-day MA of 0.36, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 56.43 is Neutral, neither overbought nor oversold. The STOCH value of 48.44 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:1143.

Link-Asia International Medtech Group Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%
1143	―	HK$96.44M	―	-0.82%	―	-25.16%	-160.31%
8147	―	HK$192.72M	37.50	―	―	21.86%	―
0110	―	HK$45.64M	―	-216.50%	―	-35.77%	-1.06%
0328	―	HK$186.73M	-1.10	―	―	-33.09%	-107.58%

Link-Asia International Medtech Group Ltd. Corporate Events

Link-Asia Proposes Scheme Mandate Limit Refreshment

Link-Asia International Medtech Group Ltd. has announced a proposed refreshment of its Scheme Mandate Limit under the 2023 Share Option Scheme. This move is intended to provide the company with greater flexibility to motivate and reward participants for their contributions to the company. The refreshment is subject to shareholder approval at the upcoming EGM and would increase the maximum number of shares that can be issued under the scheme to 10% of the issued shares as of the EGM date. The company emphasizes that this refreshment is in the best interests of both the company and its shareholders.

The most recent analyst rating on (HK:1143) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Link-Asia International Medtech Group Ltd. stock, see the HK:1143 Stock Forecast page.

China Energy Storage Completes Strategic Acquisition

China Energy Storage Technology Development Limited has completed the acquisition of the entire equity interest in a target company, making it a wholly-owned subsidiary. The acquisition, finalized on September 18, 2025, involved a consideration adjustment based on the net asset value, resulting in a final payment of HK$21,124,996. This strategic move will see the financial results of the acquired company consolidated into the group’s financial statements, potentially strengthening its market position in the energy storage sector.

The most recent analyst rating on (HK:1143) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Link-Asia International Medtech Group Ltd. stock, see the HK:1143 Stock Forecast page.

Link-Asia International Medtech Group Ltd. Announces Strategic Acquisition

Link-Asia International Medtech Group Ltd., a company incorporated in the Cayman Islands, has announced a significant acquisition. The company has entered into a Sale and Purchase Agreement to acquire the entire equity interest in a target company for HK$20,800,000, subject to adjustments. This acquisition, which will make the target company an indirect wholly-owned subsidiary, is classified as a discloseable and connected transaction under the Hong Kong Listing Rules. The transaction has been approved by the Board and deemed fair and reasonable by the independent non-executive Directors, thus exempting it from certain regulatory requirements.

The most recent analyst rating on (HK:1143) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Link-Asia International Medtech Group Ltd. stock, see the HK:1143 Stock Forecast page.

China Energy Storage Technology Reports Interim Loss Amid Revenue Decline

China Energy Storage Technology Development Limited reported its unaudited consolidated interim results for the first half of 2025, revealing a significant decline in revenue and profit compared to the same period in 2024. The company experienced a net loss of HK$16.5 million, attributed to decreased revenue and increased finance costs, which may impact its market position and stakeholder confidence.

The most recent analyst rating on (HK:1143) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Link-Asia International Medtech Group Ltd. stock, see the HK:1143 Stock Forecast page.

China Energy Storage Technology Ends Joint Placing Agreement

China Energy Storage Technology Development Limited announced the lapse of its Joint Placing Agreement due to unmet conditions by the deadline, resulting in the cessation of the planned Placing. The company assured stakeholders that this development will not adversely affect its operational or financial standing.

The most recent analyst rating on (HK:1143) stock is a Hold with a HK$0.50 price target. To see the full list of analyst forecasts on Link-Asia International Medtech Group Ltd. stock, see the HK:1143 Stock Forecast page.

China Energy Storage Technology Development Ltd. Announces Board Meeting for Interim Results

China Energy Storage Technology Development Limited has announced a board meeting scheduled for August 29, 2025. The meeting will focus on approving the interim results for the first half of 2025, considering the payment of an interim dividend, and addressing other business matters. This announcement signifies the company’s ongoing commitment to transparency and shareholder engagement, potentially impacting its market positioning and stakeholder relations.

China Energy Storage Extends Long Stop Date for Share Placement

China Energy Storage Technology Development Limited has announced a further extension of the Long Stop Date for the placement of new shares under a general mandate. The extension, now set to 19 August 2025, allows additional time for fulfilling conditions precedent in the Joint Placing Agreement. This move is seen as commercially reasonable and in the interest of the company and its shareholders, although the completion of the placing remains uncertain.